Japan To Become First Market For Troubled Brodalumab
Executive Summary
The interleukin-targeting antibody brodalumab will have its first launch worldwide this week, in Japan for various forms of psoriasis.
You may also be interested in...
LEO Pharma Gets EU Go-Ahead For Psoriasis Latecomer Brodalumab
The Danish speciality dermatology company LEO Pharma has achieved a key plank in its plans to provide products for the range of psoriasis patients with an EU go-ahead for brodalumab.
Suicide Warnings For Valeant’s Siliq Could Hinder Access To Psoriasis Treatment
While an FDA advisory committee unanimously supported approval of the plaque psoriasis drug brodalumab, several recommended a black box warning on suicide risk that could limit sales of the drug.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.